Citations

Clear

194 citation(s) found for "Siontis, K".

Evaluation of modern hematology-oncology home call: optimizing patient care, physician well-being, and trainee education
Liddell, Savannah S , Cao, Eric , Bentz, Caleb , Al-Kali, Aref , Hogan, William J , Tevaarwerk, Amye J , Siontis, Brittany L , Paludo, Jonas

Mayo Clinic

Blood Advances | September 25, 2026 | Volume: 10 | Issue: 22 | Pages: 7809-7820

10.1182/bloodadvances.2026021316 | PMID 42790416 Get It

Abstract Traditional home call, managing after-hours pager communications, remains a common component of hematology-oncology fellowship and modern practice. Little is known about these patient-related interactions and implications. The aim of this project was to characterize after-hours pager volumes and evaluate perceived impacts on care, physician well-being, and trainee education. We performed a mixed-methods study at a tertiary academic center, analyzing after-hours pager activity from 2020 to 2024 across hematology consult pagers (HCP), hematology outpatient pagers (HOP), and medical oncology pagers (MOP). A survey of hematology-oncology fellows evaluated perceptions and attitudes toward the home-call experience using free-text responses and a 5-point Likert scale. After-hours pager burden was substantial and sustained. The MOP received >3000 pages annually, with medians of 5 to 6 per weekday and 15 to 15.5 per weekend day. The HOP volume nearly doubled over the study period (960-1721 annually), with median pager volumes of 1 to 3 per weekday and 2 to 7 per weekend day. The HCP volume ranged from 594 to 768 pages annually. Survey response rate was 58% (19/33). Only 16% of fellows endorsed educational value from patient calls on MOP or HOP, and ≤5% agreed that call tasks required physician-level expertise. Respondents reported that the pager resulted in fatigue, anxiety, and social disruptions. Free-text responses revealed themes of low educational value, high nonurgent call volume, and system inefficiencies. Contemporary home call had substantial pager burdens with limited actionability, adverse effects on well-being, and low educational value. Systems engineering, including triage processes and augmented patient education, could help optimize patient care, physician well-being, and trainee education.
Clinical value of MRI in radiation-associated angiosarcoma of the breast: assessment of baseline and post-neoadjuvant disease
Sae-Kho, Tiffany Marian, Glazebrook, Katrina N. , Siontis, Brittany L, Hieken, Tina J, Jakub, James W, Baum, Christian L. , Vijayasekaran, Aparna , Okuno, Scott H. , Solanki, Malvika, Day, Courtney, Schrup, Sarah E. , Degnim, Amy C, Hieken, Tina J. , Sae-Kho, Tiffany M. , Gonzalez, Tomas V. , Hoskin, Tanya L. , Ahmed, Safia K. , Hieken, Tina J , Siontis, Brittany L. , Jakub, James W. , Solanki, Malvika , Degnim, Amy C.

Mayo Clinic

British Journal of Radiology | August 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/bjr/tqag191 | PMID 42610719 Get It

Abstract Objective To evaluate the clinical value of breast MRI in radiation-associated angiosarcoma of the breast (RAASB) for assessing disease extent at diagnosis and after neoadjuvant therapy compared with clinical examination and surgical pathology. Methods This IRB-approved retrospective study included 25 patients with breast MRIs between1995 and 2020. MRI estimated disease extent was compared to clinical exam and surgical pathology. MRI findings were evaluated for additional disease and impact on clinical management. Agreement between MRI and clinical assessment of disease was evaluated using Cohen’s kappa statistic. Results Baseline MRI demonstrated moderate agreement with clinical disease extent (Cohen’s κ = 0.44; 95% CI, 0.14-0.75). Thirteen of 24 (54%) of MRIs reflected clinical exam, 4/24 (17%) MRIs underestimated disease, and 5/24 (21%) MRIs overestimated disease. Baseline MRI changed surgical management in 4/24 (17%). In 8 patients who proceeded directly to surgery, MRI reflected pathology in 6/8 (75%). In 10 patients with post-neoadjuvant MRI, 4/10 (40%) pathology and MRI extent were similar, 5/10 (50%) MRI overestimated disease, and 1/10 (10%) MRI underestimated disease. Conclusion MRI has clinical value in assessing RAASB with the potential for significantly altering surgical management. In this small cohort, post-neoadjuvant MRI demonstrated limited additional clinical value. Larger studies are needed to define the optimal role and timing of post-neoadjuvant MRI. Advances in knowledge Baseline MRI detected additional disease not identified on initial clinical exam in 5/24 (21%) and changed surgical management in 4/24 (17%). Although baseline MRI demonstrated moderate agreement with clinical examination, post-neoadjuvant MRI frequently overestimated residual disease when compared with final pathology.
Physiology-guided cardioneuroablation for vagally mediated syncope and functional bradyarrhythmias
Kowlgi, Gurukripa N. , Pachón-M, José Carlos , Prasitlumkum, Narut , Gulati, Arvind, Yoo, Jeanwoo , Karlen, Kallie, Tan, Nicholas Y. , Sugrue, Alan , Killu, Ammar M. , Deshmukh, Abhishek , Munoz, Freddy Del‐Carpio , Siontis, Konstantinos C. , Madhavan, Malini , Friedman, Paul A. , Pachon-Mateos, Enrique, Pachon, Carlos, Acosta, Juan , Cha, Yong‐Mei , Shen, Win‐Kuang , Kowlgi, Narayan G , Prasitlumkum, Narut , Pachon, Jose C , Gulati, Arvind, Kapa, Suraj , DeSimone, Christopher V. , Noseworthy, Peter A. , Mateos, Enrique I. Pachon-, Pachon, Carlos Thiene C., Asirvatham, Samuel J.

Mayo Clinic

No container title available | August 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.08.03.26359633 Get It

Abstract Background Vagally mediated syncope and functional bradyarrhythmias can cause recurrent symptoms, injury and a need for permanent pacing, yet standard therapies do not address the underlying autonomic reflex. Cardioneuroablation (CNA) targets this mechanism, but adoption has been limited by uncertainty about patient selection, procedural endpoints and durable outcomes. Methods We studied 95 consecutive patients with vagally mediated syncope (n=78) or functional bradyarrhythmia (n=17) who underwent CNA at a single center by a single lead operator under a uniform, prospectively maintained protocol. Extracardiac vagal stimulation (ECVS) was performed before and after ablation to confirm vagally mediated sinus or atrioventricular (AV) nodal responses and to verify their attenuation. Outcomes through 1 year included clinical recurrence, quality of life, pacing burden and pacemaker extraction. Results Before ablation, ECVS provoked sinus pauses in 95.8% of patients and AV block in 91.6%; after ablation, sinus pauses were abolished in every patient and residual AV block was present in 4.2%. One-year freedom from recurrent syncope and from bradyarrhythmia-related events was 93.8% and 94.1%. Syncope burden fell from a median of 2.7 episodes per year to none, and disease-specific quality of life improved substantially (P<0.001). Among patients with pre-existing devices, atrial pacing burden fell from a median of 22% to 0%. There were no strokes, deaths or myocardial infarctions. Conclusions In this single-center cohort, physiology-guided CNA was associated with durable symptom control, improved quality of life and reduced pacing across vagally mediated bradyarrhythmia syndromes. Multicenter controlled studies are needed to confirm these findings.
Listening to the Right Ventricle: Invasive Hemodynamics to Refine Risk Before Ventricular Tachycardia Ablation
Haq, Ikram-Ul , Siontis, Konstantinos C. , Haq, Ikram U

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 23, 2026 | Volume: 37 | Issue: 8 | Pages: 1709-1710

10.1111/jce.70442 | PMID 42489247 Get It

Abstract B054: Systemic Therapy and Outcomes in Patients with Intermediate or High-Risk Solitary Fibrous Tumor
Lin, Miranda, Siontis, Brittany, Robinson, S I, Okuno, Scott, Ho, Thanh, Siontis, Brittany L. , Robinson, Steven I. , Ho, Thanh

Mayo Clinic

Cancer Research | July 18, 2026 | Volume: 86 | Issue: 14_Supplement | Pages: B054-B054

10.1158/1538-7445.rareca26-b054 Get It

Abstract Background: Solitary fibrous tumors (SFT) make up less than 5% of sarcomas. The Demicco model stratifies risk of metastasis based on age, tumor size, mitotic count, and necrosis. Patients (pts) with relapsed disease have limited options. We evaluated outcomes of systemic therapies (tx) to treat SFT. Methods: A retrospective analysis was performed of pts with intermediate-to-high risk SFT confirmed by soft tissue pathologists at a multi-site health system from 1999 – 2024. Demographics, tx, and pt outcomes were analyzed. Radiographic response was abstracted from documentation by treating provider. Results: Sixty pts had intermediate-to-high risk SFT, of which 21 pts received systemic tx. Of these, 12 were male, median age at diagnosis 62.8 years (41.0 – 82.7 yrs). Tumors originated from chest (11, 52.4%), abdomen (5, 23.8%), pelvis (4, 19.0%), and skull (1, 4.8%). All pts had surgery for primary tumor, median size 16.0 cm (7.8 – 43.0), and 14 (66.7%) had surgery at relapse. Eight pts (38.1%) had perioperative radiation therapy (RT); 12 (57.1%) had palliative RT. Five (23.8%) had ablation. Of the 21 pts, 2 (9.5%) had perioperative chemotherapy (chemo). Twenty pts (95.2%) received median 2 lines (1 – 6) of palliative systemic tx (1 pt did not pursue any). One pt had partial response on dacarbazine, otherwise best clinical response was stable disease (SD, 53.1% vascular endothelial growth factor inhibitors (VEGFi), 40% chemo) or disease progression (PD). Most pts received VEGFi: 11 pts had sunitinib (median 3.1 months, range 1.0 – 10.6 mo), 11 pts had pazopanib (4.1 mo, 0.1 – 38.7), and 10 pts had temozolomide/bevacizumab (5.6 mo, 1.0 – 15.8). VEGFi was dose reduced or held in 59.4% . Discontinuation due to toxicity occurred in 34.4% of pts treated with VEGFi vs 26.7% of pts treated with chemo. Five pts received liposomal doxorubicin (median 4.8 mo, range 3.5 – 11.3). Four pts had doxorubicin with dacarbazine, ifosfamide or olaratumab (2.8 mo, 0.7 – 8.5). Two pts received dacarbazine (1.9 and 9.6 mo, respectively), and 2 pts received gemcitabine/docetaxel (0.9 and 4 mo). Eribulin and trabectedin (1 pt, respectively) were used for less than 1 mo. Tx was held or dose reduced for 1 pt on doxorubicin/dacarbazine and 1 pt on gemcitabine/docetaxel. Three pts had immunotherapy (IO, 2 pts pembrolizumab, 1 pt nivolumab/ipilimumab) and stopped for PD (2 pts) or toxicity (1 pt) after 2 mo or less. Two pts participated in clinical trials. Median time from primary surgery to relapse was 2.0 yrs (0.0 – 12.3). Sixteen pts died (76.2%), 14 from SFT. Median time from relapse to death or last contact was 4.1 yrs (0.5 – 14.7). Median overall survival from diagnosis to death/last contact was 6.6 yrs (0.6 – 27.0). Conclusion: Perioperative chemo was rarely used to treat intermediate-to-high risk SFT. For relapse, VEGFi use was more common than chemo, with more pts achieving SD and receiving longer duration of tx. VEGFi had greater toxicity and subsequent discontinuation. No benefit was observed in few pts who received IO. Clinical trial participation was uncommon. Citation Format: Miranda Lin, Brittany Siontis, Steven Robinson, Scott Okuno, Thanh Ho. Systemic Therapy and Outcomes in Patients with Intermediate or High-Risk Solitary Fibrous Tumor [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Breaking Barriers in the Fight against Rare Cancers; 2026 Jul 18-20; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(14_Suppl):Abstract nr B054.
Conduction system vs. biventricular pacing in heart failure with reduced ejection fraction: a meta-analysis of randomized controlled trials
Karakasis, Paschalis , Vlachos, Konstantinos , Siontis, Konstantinos C. , Cano, Óscar , Tzeis, Stylianos , Strik, Marc , Pamporis, Konstantinos , Leventopoulos, Georgios , Antoniadis, Antonios P. , Jaı̈s, Pierre , Burri, Haran , Fragakis, Nikolaos , Karakasis, Paschalis , Pamporis, Konstantinos , Antoniadis, Antonios P , Jaïs, Pierre , Burri, Haran

Mayo Clinic

Europace | July 1, 2026 | Volume: 28 | Issue: 8 | Pages: No page available

10.1093/europace/euag170 | PMID 42586561 Get It

Abstract Aims Conduction system pacing (CSP) has emerged as a physiologic alternative to cardiac resynchronization therapy (CRT) with biventricular pacing (BiVP) in heart failure with reduced ejection fraction (HFrEF), yet its comparative effects remain uncertain. This meta-analysis sought to compare outcomes of CSP vs. BiVP in patients with HFrEF undergoing CRT. Methods and results MEDLINE, Embase, Scopus, and the Cochrane Database were searched through 4 May 2026. Randomized controlled trials (RCTs) were synthesized using random-effects meta-analysis. Thirteen RCTs including 1320 participants were analysed (657 CSP, 663 BiVP). Conduction system pacing was associated with a lower risk of the composite of hospitalization for heart failure (HHF) or all-cause mortality compared with BiVP (46 vs. 83 events; odds ratio [OR] 0.51, 95% confidence interval [CI] 0.28–0.93). No significant differences were observed for HHF alone (OR 0.68, 95% CI 0.36–1.27) or all-cause mortality (OR 0.75, 95% CI 0.36–1.58). Conduction system pacing was associated with greater improvement in the 6-min walk distance (mean difference [MD] 21.53 m, 95% CI 4.33–38.73) and New York Heart Association functional class (standardized mean difference [SMD] −0.27, 95% CI −0.47 to −0.07), but not quality of life. Conduction system pacing also reduced QRS duration compared with BiVP (MD −10.94 ms, 95% CI −17.55 to −4.34), with no significant differences in left ventricular ejection fraction, left ventricular end-systolic volume, overall pacing threshold, total procedure time, fluoroscopy time, any complication, or reintervention. Conclusion In patients with HFrEF undergoing CRT, CSP is associated with lower composite risk of HHF or all-cause mortality compared with BiVP. Conduction system pacing is also associated with improved functional capacity, without significant differences in safety or procedural outcomes.
Sex specific differences patients with arrhythmic mitral valve prolapse with in sustained arrhythmias - a SAVE-MVP collaboration sub analysis
Heller, E, Aabel, E W, Ollitrault, P, Baudinaud, P, Bergonti, M, Bhardwaj, P K, Delling, F, Riva, M De, Haddad, C H, Huttin, O, Krebsova, A, Siontis, K, Laredo, M, Nagy, A, Sabbag, A, Heller, Eyal , Aabel, E W, Ollitrault, Pierre , Baudinaud, Pierre , Bergonti, Marco , Bhardwaj, Priya , Delling, Francesca N. , Huttin, Olivier , Krebsová, Alice , Siontis, Konstantinos C. , Laredo, Mikael , Nagy, A, Sabbag, A

Mayo Clinic

Europace | June 25, 2026 | Volume: 28 | Issue: Supplement_1 | Pages: No page available

10.1093/europace/euag105.1051 Get It

Abstract Background Arrhythmogenic mitral valve prolapse (AMVP) is increasingly recognized as a cause of sustained ventricular arrhythmias (VA) and sudden cardiac death. Although prior studies have identified clinical and imaging risk markers in AMVP, it remains unclear whether the arrhythmogenic phenotype differs between women and men. Purpose To investigate sex-specific differences in clinical profiles, structural substrates, and arrhythmia presentations in patients with AMVP who experienced sustained VA. Methods We conducted a sex-based sub-analysis of a multicenter cohort (35 centers from 15 countries) of patients with AMVP and sustained VA. Participants were grouped by sex and by initial arrhythmia type (sustained monomorphic ventricular tachycardia [SMVT] vs ventricular fibrillation [VF]). Data collected included clinical history, ECG findings, echocardiographic measurements, and cardiac MRI (CMR) markers, such as late gadolinium enhancement (LGE) patterns and mitral annular disjunction (MAD). These factors were compared across groups. Results The study comprised 129 women (57%) and 96 men (43%). Women were diagnosed at younger ages (39±16 years vs. 49±16 years, p&lt;0.03) and had more frequently a family history of MVP (22% vs 10%, p=0.027). MAD was significantly more common in women (66% vs 48%, p=0.015) while LGE was more frequently observed in men than women (N=39 (72%) vs N=41 (53%), p=0.028), with no significant regional patterns (myocardial and/or papillary muscle). ECG T-wave inversion (p=0.627), PVC burden (p&gt;0.03) and arrhythmia types were similar in men and women. However, stress was a more often commonly recognized as the initiating trigger for VA in men than in women (38% [N=24] vs. 18% [N=18], p&lt;0.05). The overwhelming majority of VA were initiated by PVCs in both sexes with no differences in the initiating mechanisms. Conclusion In patients with AMVP presenting with sustained VA, the arrhythmic phenotype and initiating mechanisms are similar between sexes, although stress was a significantly stronger trigger for VA in men. Women more often exhibited MAD, whereas LGE was more frequent in men. These findings suggest that structural and tissue-based markers, rather than sex alone, contribute to the development of malignant arrhythmias in AMVP.
The ATLAS study: A first-in-human phase 1/2 trial of [Ac-225]RTX-2358 in patients with relapsed or refractory soft tissue sarcoma.
Tap, William D., Nakazawa, Michael S. , Shultz, David, Somaiah, Neeta , Balser, John, Hayward, Colin RW, Hesterman, Jacob, Jardine, Vicki, Redmond, Christine, Babich, John, D'Angelo, Sandra P , Tap, William D. , Mangla, Ankit , Schwartz, Gary K. , Shultz, David Benjamin , Singh, Arun S., Siontis, Brittany L. , Hayward, Colin R.W. , Hesterman, Jacob , Jardine, Vicki, Redmond, Christine

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps11598 Get It

TPS11598 Background: Fibroblast Activation Protein (FAP) is expressed on the surface of cancer-associated fibroblasts and is involved in the formation, maintenance, and spread of tumors. Sarcoma frequently demonstrates high expression of FAP on the tumor cells themselves in contrast to other solid tumors, where it is mainly expressed on CAFs within the tumor stroma. Radioligand therapies utilizing alpha emitting isotopes such as Ac-225 have emerged as promising treatment strategies across multiple targets and indications in oncology. Ac-225 and its daughter radionuclides emit high-energy alpha particles capable of inducing double-stranded DNA breaks, leading to significant cytotoxic effects within cells. Early clinical data for other Ac-225-labeled compounds have shown promising outcomes, particularly in settings where traditional therapies have failed. [Ac-225] RTX-2358 (Ratio Therapeutics Inc, Boston, MA) is a novel FAP-targeted radioligand designed for specific high-affinity binding, resulting in prolonged tumor residence and limited normal tissue uptake. This sustained tumor retention leads to extended delivery of cytotoxic radiation to FAP-expressing tumors. A beta-emitting analog, [Lu-177]RTX-2358, has been administered to more than 25 patients under the German §13.2b compassionate use framework across multiple tumor types. Longitudinal SPECT imaging performed as late as 14 days after administration demonstrated persistent tumor retention with minimal washout. Based on time–activity curve analysis from these data, tumor biological half-time is estimated to be well in excess of 1,000 hours. Renal clearance was observed to be consistent with that reported for established lutetium-177–labeled radioligand therapies. Methods: This study is a seamless Phase 1 / 2 dose escalation study. The Phase 1 portion consists of a 3 x 3 dose escalation design, with patients treated in 3 planned dose escalation cohorts (7.5, 11.25 and 15 MBq) with up to 6, 8-week cycles of [Ac-225]RTX-2358. Backfill of phase 1 cohorts is permitted to facilitate selection of the recommended administered activity level for the subsequent Phase 2 expansion cohort. Dose escalation / de-escalation decisions will be made by a Safety Review Committee. Patients over 18yrs with a history of histologically confirmed relapsed or refractory soft tissue sarcoma (measurable disease per RECIST v1.1) are eligible if they have a positive [Cu-64]LNTH-1363S FAP PET, an ECOG PS 0 to 1, and adequate organ reserve and renal function. Recruitment of the first cohort was completed in December 2025. The ATLAS Study: NCT07156565 Clinical trial information: NCT07156565 .
Phase 3 study (APROMISS) of catequentinib hydrochloride (AL3818) monotherapy in patients with advanced alveolar soft part sarcoma (ASPS).
Trent, Jonathan C., Somaiah, Neeta , Chugh, Rashmi, Fan, Zhengfu, Jones, Robin Lewis, Tine, Brian Andrew Van, Bui, Nam, Chawla, Sant P. , Shen, Zan, Vincenzi, Bruno, Keedy, Vicki L. , Bui, Nam Q. , Bui, Nam , Stacchiotti, Silvia , Trent, Jonathan C. , Chmielowski, Bartosz , Chugh, Rashmi , Jones, Robin Lewis, Burgess, Melissa , Vincenzi, Bruno , Pollack, Seth M. , Siontis, Brittany L.

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 11502-11502

10.1200/jco.2026.44.16_suppl.11502 Get It

11502 Background: To report results from the open-label alveolar soft part sarcoma (ASPS) cohort of the phase III APROMISS trial (NCT03016819) evaluating Catequentinib hydrochloride (AL3818), an oral multitargeted receptor tyrosine kinase inhibitor, in adults with advanced or metastatic ASPS. Methods: Adult patients with pathologic and molecularly confirmed advanced ASPS, either treatment-naive or previously treated (excluding cediranib), were enrolled in the open-label, non-randomized ASPS cohort of the phase III APROMISS trial conducted across the United States, Asia, and Europe. Catequentinib hydrochloride was administered orally at 12 mg once daily in 21-day cycles (14 days on/7 days off) until disease progression, toxicity, or death. The primary endpoint was objective response rate (ORR) assessed per RECIST by Blinded Independent Central Review (BICR) (predefined threshold: 31%). Secondary endpoints included duration of response (DOR) with a predefined target of =/>6 months, progression free survival (PFS) and overall survival (OS). Results: From July 2017 to August 2022, a total of 56 patients entered the trial; 56 patients were evaluable for the primary endpoint. Median (m-) age was 29.5 years (range: 18 – 66), with 24 female and 32 male. Best overall response included 1/56 complete response (1.8%), 14/56 partial responses (25.0%), 36/56 stable disease (64.3%), and 3/56 (5.4%) progressive disease. RECIST ORR by BICR was 26.8% (95% CI, 15.8–40.3); m-DOR was 22.57 months (95%CI: 10.38-NE). The study data was collected close to 8 years for all patients. mPFS was 18.33 months (95% CI, 14.19–23.13), with 6- and 12-month progression-free rates of 88.77% (95% CI, 76.68–94.79) and 65.54% (95% CI, 50.42–77.06), respectively. mOS was 59.27 months (95% CI, 44.09–NE), with 6- and 12-month overall survival rates of 94.64% (95% CI, 84.30–98.24) and 90.81% (95% CI, 79.30–96.08), respectively. Overall, 27/56 (48.2%) patients experienced grade ≥3 treatment-related adverse events, most commonly diarrhea (50.0%), hypertension (44.6%), fatigue (37.5%), nausea (35.7%), and palmar-plantar erythrodysesthesia syndrome (30.4%); one patient (1.8%) had a grade 5 event (respiratory failure). Conclusions: Catequentinib hydrochloride demonstrated meaningful antitumor activity and durable responses in adults with advanced ASPS. Despite the ORR of 26.8% slightly below the predefined 31% threshold, disease control was prolonged, with a m-DOR exceeding 22 months. Favorable PFS and OS outcomes, together with a manageable safety profile, support its clinical benefit in this ultra-rare sarcoma. Clinical trial information: NCT03016819 .
Empiric and Trigger‐Guided Superior Vena Cava Isolation in AF Ablation: Systematic Review and Meta‐Analysis
Sehrawat, Ojasav , Garg, Vasudha, Foo, Cher Y. , Khandekar, Ninad , Matai, Pallavi, ASIRVATHAM, SAMUEL, Siontis, Konstantinos C., Noseworthy, Peter A., Asirvatham, Samuel J. , Foo, Cher Ying , Asirvatham, Samuel J , Xue, Chao , Siontis, Konstantinos C. , Noseworthy, Peter A.

Mayo Clinic

Pacing and Clinical Electrophysiology | May 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/pace.70296 | PMID 42154216 Get It

ABSTRACT Background Superior vena cava isolation (SVCI) is performed as an adjunct to pulmonary vein isolation (PVI) for atrial fibrillation, yet whether an empiric or trigger‐guided strategy is preferable remains uncertain. Prior meta‐analyses have been largely restricted to index procedures in paroxysmal AF and have not explicitly stratified by ablation strategy. We sought to address these gaps through a systematic review of available randomized evidence. Methods Major databases were searched through November 2025 for RCTs comparing PVI+SVCI versus PVI alone. Trials were stratified by strategy: empiric SVCI (performed irrespective of SVC ectopy) or trigger‐guided SVCI (performed only upon demonstrated SVC triggers). The primary outcome was atrial tachyarrhythmia recurrence (≥30 s) beyond the blanking period. Random‐effects models, pre‐specified subgroup analyses, meta‐regression, and GRADE certainty assessment were performed. Results Eight RCTs ( n = 1231) were included; most enrolled paroxysmal AF, while two incorporated non‐paroxysmal AF subtypes and one evaluated repeat ablation procedures. Overall, SVCI+PVI significantly reduced recurrence versus PVI alone (97/604 vs. 135/627; RR 0.77, 95% CI 0.61–0.97; p = 0.03; I 2 = 0%). On stratified analysis, empiric SVCI demonstrated a significant recurrence reduction (RR 0.70, 95% CI 0.53–0.92; p = 0.01; I 2 = 0%), while trigger‐guided SVCI did not reach statistical significance (RR 0.80, 95% CI 0.37–1.74; p = 0.57; I 2 = 52%). In paroxysmal AF ( n = 1038), adjunctive SVCI significantly reduced recurrence compared with PVI alone (RR 0.68, 95% CI 0.52–0.90; p = 0.01; I 2 = 0%). Fluoroscopy time was longer with SVCI; total procedure duration was comparable. Major complications were infrequent but numerically higher with SVCI+PVI (15/604 vs. 7/627; RR 1.96, 95% CI 0.87–4.38; p = 0.10). Meta‐regression identified no significant effect modifiers. GRADE certainty was high for overall and empiric analyses, and moderate for trigger‐guided SVCI. Conclusions Empiric SVCI significantly reduced AT/AF recurrence as an adjunct to PVI, while trigger‐guided SVCI did not demonstrate a significant benefit. These findings suggest SVC isolation confers benefit independent of prior trigger documentation, supporting the role of empiric SVCI as an adjunct to AF ablation.